Contributions
Abstract: P709
Type: Poster
Abstract Category: Therapy - disease modifying - Risk management for disease modifying treatments
Introduction: The risk of Progressive Multifocal Leucoencephatolopaty (PML) caused by JC virus (JCV) is increasing in Multiple Sclerosis (MS) patients treated with some disease modifying therapies (DMTs). JCV seroconversion has been related to Natalizumab use and its rate is about 3% in the general population. However, some studies have been reported higher rates in MS patients (more than 20%).
Aim: To analyse the VJC seroconversion rate in MS patients with any DMT, included Natalizumab and to study their baseline characteristics in order to find a seroconverter profile for the VJC.
Material and methods: Retrospective review of VJC MS patients from Virgen Macarena Hospital, Seville, Spain, whose first JCV serological status was negative, underwent a second serological VJC evaluation. The collected data included baseline and MS characteristics.
The Stratify VJC test has been done in Denmarck using ELISA test. Index higher than 0.4 was considered positive.
Results: 101 patients were studied, 64 of them were being treated with Natalizumab/Group 1 and 37 with others DMT/Group 2 (BRACE therapy (35) and Fingolimod (2)). 15% became positive in the second evaluation, 17% in Group 1 and 13,51% Group2 without significant statistical difference.
No differences were found beetween seroconverters or not in any baseline or MS characteristics.
Conclusion: Our results show that the seroconversion rate is not related with Natalizumab treatment. It is imperative to find an aceptable seroconverter profile in order to avoid PML cases. We didn´t find any characterisitic that could predict the PML risk.
Disclosure: Sara Eichau received research funding, compensation for travel or speaker honoraria from Biogen, Novartis, Genzyme and Almirall.
Abstract: P709
Type: Poster
Abstract Category: Therapy - disease modifying - Risk management for disease modifying treatments
Introduction: The risk of Progressive Multifocal Leucoencephatolopaty (PML) caused by JC virus (JCV) is increasing in Multiple Sclerosis (MS) patients treated with some disease modifying therapies (DMTs). JCV seroconversion has been related to Natalizumab use and its rate is about 3% in the general population. However, some studies have been reported higher rates in MS patients (more than 20%).
Aim: To analyse the VJC seroconversion rate in MS patients with any DMT, included Natalizumab and to study their baseline characteristics in order to find a seroconverter profile for the VJC.
Material and methods: Retrospective review of VJC MS patients from Virgen Macarena Hospital, Seville, Spain, whose first JCV serological status was negative, underwent a second serological VJC evaluation. The collected data included baseline and MS characteristics.
The Stratify VJC test has been done in Denmarck using ELISA test. Index higher than 0.4 was considered positive.
Results: 101 patients were studied, 64 of them were being treated with Natalizumab/Group 1 and 37 with others DMT/Group 2 (BRACE therapy (35) and Fingolimod (2)). 15% became positive in the second evaluation, 17% in Group 1 and 13,51% Group2 without significant statistical difference.
No differences were found beetween seroconverters or not in any baseline or MS characteristics.
Conclusion: Our results show that the seroconversion rate is not related with Natalizumab treatment. It is imperative to find an aceptable seroconverter profile in order to avoid PML cases. We didn´t find any characterisitic that could predict the PML risk.
Disclosure: Sara Eichau received research funding, compensation for travel or speaker honoraria from Biogen, Novartis, Genzyme and Almirall.